UK Politicians Call for Full Competition Review of Netflix’s Warner Bros Discovery Deal 
Meta Faces Lawsuit Over Alleged Approval of AI Chatbots Allowing Sexual Interactions With Minors 
China Approves First Import Batch of Nvidia H200 AI Chips Amid Strategic Shift 
Alibaba-Backed Moonshot AI Unveils Kimi K2.5 to Challenge China’s AI Rivals 
Volkswagen CEO Oliver Blume Faces Crucial Year as Investors Demand Turnaround Results 
C3.ai in Merger Talks With Automation Anywhere as AI Software Industry Sees Consolidation 
The Maire - EuroChem Case: Three Lessons for Global Business 
Micron to Expand Memory Chip Manufacturing Capacity in Singapore Amid Global Shortage 
Zijin Mining Shares Hit Record High on $4 Billion Allied Gold Acquisition 
LVMH Investors Watch Earnings Closely as Luxury Recovery Faces New Challenges 
Citigroup Faces Lawsuit Over Alleged Sexual Harassment by Top Wealth Executive 
Microsoft Wins Approval to Build 15 New Data Centers in Wisconsin 
ASML’s EUV Monopoly Powers the Global AI Chip Boom 
Anthropic Raises 2026 Revenue Outlook by 20% but Delays Path to Profitability 
Sam Altman Criticizes ICE Enforcement as Corporate Leaders Call for De-Escalation 
ANTA Sports to Acquire Major Stake in Puma in €1.5 Billion Deal, Signaling Strategic Revival 
BYD and Exxon Mobil Strengthen Hybrid Technology Partnership 
DALLAS, May 18, 2017 -- TissueGen® Inc., developer of ELUTE® fiber, a groundbreaking biodegradable fiber format for advanced drug delivery, nerve regeneration, and tissue engineering, was awarded the title of Most Innovative Small Size Company by the World Textile Information Network (WTiN), publisher of international technical textiles magazine Future Textiles (formerly known as Future Materials).
TissueGen Founder and CSO, Dr. Kevin Nelson, and President and CEO, Christopher Knowles, accepted the award at the Future Textiles Award Gala in Frankfurt, Germany this past week. Organized by WTiN, the third edition of the biennial awards celebrated the best innovations in the technical textiles industry.
TissueGen’s patented process for manufacturing commercially available ELUTE® fiber occurs at or below body temperature thereby preserving the biologic activity of incorporated biologics and pharmaceutical compounds. ELUTE fiber technology enables controlled sustained delivery of a broad range of sensitive biologics and pharmaceuticals directly at the topical application or implant site and may potentially orchestrate and improve the healing process. ELUTE fiber enables tissue engineering and regenerative medicine applications never before possible.
“We are honored to receive this recognition from WTiN as further testament to the groundbreaking work conducted by our scientists at TissueGen,” said Knowles. “We were privileged to participate in this special event and congratulate all the winners and finalists.”
A full list of winners is available here.
About TissueGen
TissueGen® Inc. is the developer of ELUTE® fiber, a groundbreaking biodegradable fiber format for advanced drug delivery, nerve regeneration, and tissue engineering. TissueGen manufactures biodegradable polymer-based fibers with the broadest drug delivery capabilities available today. ELUTE fiber can directly replace standard fibers used in medical devices currently on the market and may provide significantly improved clinical outcomes by delivering sensitive therapeutic agents directly at the implant or topical application site in controlled, sustained release profiles. ELUTE fiber may enable medical device developers to guide the body’s healing and regenerative processes.
For more information, please visit www.tissuegen.com.
For more information contact: Jordan Bouclin SVM Public Relations 401-490-9700 [email protected]
